Journey Medical Expands Pharmacy Coverage for Emrosi

The latest announcement is out from Journey Medical Corp ( (DERM) ).

On July 14, 2025, Journey Medical Corporation announced an expansion in pharmacy benefit coverage for Emrosi™, a treatment for inflammatory lesions of rosacea in adults. The coverage increased from 29% to 65% of commercial lives in the United States, supporting the adoption of Emrosi as prescription demand rises. This expansion is expected to facilitate further growth in total prescription demand, positioning Emrosi as a potential standard of care for rosacea treatment.

The most recent analyst rating on (DERM) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Journey Medical Corp stock, see the DERM Stock Forecast page.

Spark’s Take on DERM Stock

According to Spark, TipRanks’ AI Analyst, DERM is a Neutral.

Journey Medical Corp faces significant financial challenges, primarily due to declining revenues and negative profitability. However, recent strategic initiatives and product launches provide a positive outlook, supported by improved market positioning and financial metrics. The stock’s technical indicators are mixed, and the valuation remains a concern due to losses. The overall score reflects a cautious optimism based on potential growth catalysts.

To see Spark’s full report on DERM stock, click here.

More about Journey Medical Corp

Journey Medical Corporation is a commercial-stage pharmaceutical company that focuses on selling and marketing FDA-approved prescription pharmaceutical products for dermatological conditions. The company markets eight FDA-approved prescription drugs and is based in Scottsdale, Arizona. It was founded by Fortress Biotech, Inc.

Average Trading Volume: 127,823

Technical Sentiment Signal: Buy

Current Market Cap: $166.6M

See more insights into DERM stock on TipRanks’ Stock Analysis page.